default author photo

Liyun Miao

Nanjing University - Department of Respiratory Medicine

China

SCHOLARLY PAPERS

5

DOWNLOADS

442

TOTAL CITATIONS

0

Scholarly Papers (5)

1.

Sintilimab Plus Bevacizumab Biosimilar IBI305, and Chemotherapy for Patients with EGFR-Mutant Nonsquamous NSCLC Who Progressed on EGFR-TKI Therapy (ORIENT-31): Interim Results from a Randomized, Double-Blind, Phase 3 Study

Number of pages: 38 Posted: 18 Mar 2022
Shanghai Jiao Tong University (SJTU) - Shanghai Lung Cancer Center, Zhengzhou University - Henan Provincial People's Hospital, Shanghai Jiao Tong University (SJTU) - Department of Medical Oncology, Jilin Cancer Hospital - Department of Oncology, Zhengzhou University - Henan Cancer Hospital, Peking University - Department of Thoracic Medical Oncology, Peking University - Department of Thoracic Medical Oncology, Huazhong University of Science and Technology - Hubei Cancer Hospital, Shandong First Medical University - Department of Oncology, Xuzhou Central Hospital, Nanjing University - Department of Respiratory Medicine, Hebei Medical University, Jilin University (JLU) - Cancer Center, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Zhengzhou University - Department of Oncology, Xiamen University, Nanjing University, Sichuan University - Department of Respiratory and Critical Care Medicine, Qingdao University - Affiliated Hospital, Innovent Biologics, Inc. - Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc. - Department of Biostatistics and Information, Eli Lilly and Company, Ltd - Department of Oncology Medical Strategy, Eli Lilly and Company, Ltd - Clinical Design, Delivery & Analytics, Innovent Biologics, Inc. - Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc. - Department of Biostatistics and Information and Innovent Biologics, Inc. - Department of Medical Science and Strategy Oncology
Downloads 135 (540,814)

Abstract:

Loading...

sintilimab, IBI305, NSCLC, EGFR

2.

Toripalimab Plus Chemotherapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (Choice-01): Final Os and Biomarker Exploration of a Randomized, Double-Blind, Phase 3 Trial

Number of pages: 37 Posted: 02 Aug 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Zhengzhou University - Henan Provincial People's Hospital, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Jilin Cancer Hospital, China Medical University - Medical Oncology Department of Thoracic Cancer, Guangdong Pharmaceutical University - Department of Medical Oncology, Xuzhou Central Hospital, Jiangnan University - Affiliated Hospital, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Harbin Medical University, Wenzhou Medical University - Taizhou Hospital of Zhejiang Province, Linyi Cancer Hospital - Department of Medical Oncology, Zhejiang University - Second Affiliated Hospital, The First Affiliated Hospital of Guangxi Medical University, Shanghai Jiao Tong University (SJTU) - Department of Respiratory and Critical Care Medicine, Tangshan People’s Hospital, Shandong University - Shandong Cancer Hospital, Qingdao Central Hospital, ZhongDa Hospital of Southeast University, Huazhong University of Science and Technology - Department of Medical Oncology, Nanchang University - First Affiliated Hospital, Zhengzhou University - Henan Cancer Hospital, Government of the People's Republic of China - Second People's Hospital of Yibin, Peking University - Department of Thoracic Medical Oncology, Nanjing University - Medical School, Xiamen University - First Affiliated Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Zhengzhou University - Department of Oncology, Xinjiang Medical University - Affiliated Tumor Hospital, China Medical University - Department of Medical Oncology, Qingdao University - Affiliated Hospital, Nanchang University - Department of Medical Oncology, Shandong University - Qilu Hospital, Shanghai Pulmonary Hospital, Tianjin Medical University - Department of Medical Oncology, Nanjing University - Department of Respiratory Medicine, Anhui Provincial Cancer Hospital, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Guangzhou Medical University - Second Affiliated Hospital, Army Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Tongji University - Department of Respiratory and Critical Care Medicine, Nantong Tumor Hospital - Department of Medical Oncology, First People's Hospital of Changzhou, Chongqing Medical University - Second Affiliated Hospital, Jilin University (JLU) - Cancer Center, Shanghai Jiao Tong University (SJTU) - Ruijin Hospital of Shanghai, Yangzhou University - Subei People's Hospital of Jiangsu Province, Anhui Provincial Cancer Hospital, Shanxi Provincial People's Hospital, Shanxi Provincial People's Hospital, Chinese Academy of Medical Sciences - Cancer Hospital, Nanjing Medical University - Nanjing First Hospital, Nanjing Medical University - Department of Oncology, ChangZhou Cancer Hospital, Nantong University - Department of Respiratory Medicine, First Hospital of Jiaxing, Fujian Provincial Cancer Hospital, Ground Force Medical University - Xinqiao Hospital, Xi’an Jiaotong University, Health Science Center, First Affiliated Hospital, TopAlliance Biosciences, TopAlliance Biosciences, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Shanghai Junshi Biosciences Co., LTD, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology
Downloads 105 (669,616)

Abstract:

Loading...

Non-small cell lung cancer, overall survival, immunotherapy, biomarker

3.

Reactogenicity and Immunogenicity of Heterologous ChAdOx1-nCoV19 and BNT162b2 Vaccination: A Systematic Review and Meta-Analysis of the Heterologous COVID-19 Vaccination Outcomes

Number of pages: 33 Posted: 13 Sep 2021
China Pharmaceutical University - Institute of Pharmaceutical Sciences, Nanjing University - Clinical Stem Cell Center, China Pharmaceutical University - Department of Pharmacoeconomics, China Pharmaceutical University - Department of Pharmacoeconomics, University of Alabama at Birmingham - Department of Biochemistry and Molecular Genetics, Huangshi Love & Health Hospital - Department of Infectious Diseases, Nanjing University - Department of Respiratory and Critical Care Medicine, Nanjing University - Department of Respiratory Medicine, Nanjing Yuhua Hospital (Yuhua Branch of Nanjing First Hospital) - Clinical Laboratory, Nanjing University - Clinical Stem Cell Center and China Pharmaceutical University - Institute of Pharmaceutical Sciences
Downloads 89 (747,755)

Abstract:

Loading...

COVID-19, SARS-CoV-2, heterologous vaccination, immunogenicity, meta-analysis

4.

Efficacy of Pemetrexed-Based Chemotherapy in Advanced NSCLC Chinese Patients with NRG1 Fusions by TNA Sequencing: A Multicenter Study

Number of pages: 19 Posted: 19 Aug 2022
Chinese Academy of Sciences (CAS) - Institute of Basic Medicine and Cancer (IBMC), Nanjing Medical University - Department of Respiratory Medicine, Nanchang University - Department of Oncology, Zhejiang University - Institute of Translational Medicine, Central South University - Department of Medical Oncology, Wenzhou Medical University - Affiliated Taizhou Hospital, Tianjin Medical University - Derpartment of Integrative Oncology, Fujian Medical University - Fujian Cancer Hospital, Xiamen University - Department of Medical Oncology, affiliation not provided to SSRN, Fujian Medical University, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Central South University - Hunan Cancer Hospital, affiliation not provided to SSRN, Nanjing University - Department of Respiratory Medicine, Shanxi Bethune Hospital, Xi'an Jiaotong University (XJTU) - Department of Oncology, affiliation not provided to SSRN, Zhejiang Cancer Hospital, Zhejiang Cancer Hospital, affiliation not provided to SSRN, Nanjing Medical University and Chinese Academy of Sciences (CAS) - Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Downloads 69 (883,195)

Abstract:

Loading...

NRG1, non-small cell lung cancer, chemotherapy, pemetrexed, efficacy

5.

Cerebrospinal Fluid Cell Free DNA Demonstrates Unique Genomic Alterations in Non-Small Cell Lung Cancer with Leptomeningeal Metastasis

Number of pages: 37 Posted: 01 Mar 2020
Nanjing University - Department of Respiratory Medicine, Nanjing University - Department of Radiology, Nanjing University - Department of Respiratory Medicine, Nanjing University - Department of Respiratory Medicine, Nanjing University - Department of Respiratory Medicine, Nanjing University - The Affiliated Drum Tower Hospital, Nanjing University - Department of Respiratory Medicine, Geneseeq Technology Inc. - Nanjing Geneseeq Technology Inc., Wannan Medical College, Nanjing Medical University, Nanjing University - Department of Respiratory Medicine and Nanjing University - Department of Respiratory Medicine
Downloads 44 (1,133,231)

Abstract:

Loading...

Non-small cell lung cancer, Leptomeningeal metastasis, Cerebrospinal fluid, Liquid biopsy